Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Eli Lilly (LLY) beats profit forecast amid soaring weight-loss drug demand
February 6, 2024 6:58 AM EST(Updated - February 6, 2024 8:26 AM EST)
Investing.com -- Eli Lilly (NYSE: LLY) has reported fourth-quarter revenue that topped estimates thanks in large part to soaring demand for its weekly diabetes injection.
The U.S. drugmaker's treatment -- branded as Mounjaro -- is in a race with a rival version from Denmark's Novo Nordisk to... More
